Form 4 for NVCT Nuvectis Pharma, Inc.
Accepted 2023-01-13 00:00:00 ET · period of report 2023-01-12 · accession 0001104659-23-003864 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-01-13 | 2023-01-12 | NVCT | BENTSUR RON | COB, CEO, Dir, 10% | A - Grant | $0.00 | +210.0K | 3.23M | +7% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-01-12 | A | A | 210,000 | $0.00 | 3,225,459 | D | — | — | (F1) The restricted stock units will vest according to the following schedule: one-third on each of 01/12/2024, 01/12/2025, and 01/12/2026. (F2) Includes 96,759 shares of restricted stock and 330,000 restricted stock units. |